03.13.2017, FIT Group JSC (code FIT) has announced to buy more 1 million shares of Cuu Long Pharmaceutical JSC.
With this plan, after completing the purchase, FIT will increase its ownership in DCL from 69.95% to 71.72% of charter capital. Subscription period of this transaction is expected from 03/16/2017 to 14/04/2017.
2017, DCL has set a plan to achieve net sales of 914 billion, nearly up to 24%; profit after tax of 96 billion, respectively up to 24%, , and 7% compared to 2016 with 738 billion in net sales and 90 billion profit after tax.
2016 is the 3rd consecutive year, DCL achieved business growth, while profit after tax increased by 50% compared to, DCL impressed not only on business results, but also successful implementation the acquisitions of Euvipharm, Valeant’s pharmaceutical companies – the most modern factory in Vietnam.
In coming period, with the investment of the FIT Group JSC, DCL expected to expand into new areas and produce oncology products by established Benovas oncology JSC.
